tiprankstipranks
Trending News
More News >
Becton Dickinson And Company (BDX)
NYSE:BDX
Advertisement

Becton Dickinson (BDX) AI Stock Analysis

Compare
2,033 Followers

Top Page

BDX

Becton Dickinson

(NYSE:BDX)

Rating:70Outperform
Price Target:
$199.00
▲(8.37%Upside)
Becton Dickinson's overall score reflects a solid financial foundation and strategic initiatives, tempered by valuation concerns and market challenges. Strong EPS growth and strategic U.S. investments are key positives, but revenue guidance revisions and external pressures, especially in China, are notable risks.
Positive Factors
Earnings
The deal is expected to be accretive to adjusted EPS in the first year, which suggests immediate financial benefits for the company.
Shareholder Value
BDX will receive a cash distribution of approximately $4B, half of which will be used for share repurchases, potentially increasing the value for shareholders.
Strategic Vision
The deal for BDX focuses the group down to the core MedTech franchise, which is critical.
Negative Factors
Complexity
Investors may take time to give BDX credit for the deal due to it being structured as an RMT, which involves complexities.
Revenue Risks
There is a perceived risk in the RemainCo revenue estimates, which makes the upcoming earnings as crucial as the deal announcement.
Shareholder Decisions
BDX shareholders will have to decide what to do with their shares in new-WAT post close and may need to hold them for a longer duration to realize full value, involving time value of money cost and equity risk.

Becton Dickinson (BDX) vs. SPDR S&P 500 ETF (SPY)

Becton Dickinson Business Overview & Revenue Model

Company DescriptionBecton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
How the Company Makes MoneyBecton Dickinson makes money through the sale of its medical devices, laboratory equipment, and diagnostic products to healthcare institutions, clinical laboratories, and the pharmaceutical industry. The company's revenue streams are diversified across its three main segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical generates revenue through the sale of medication delivery systems, diabetes care products, and pharmaceutical systems. BD Life Sciences earns income from providing products for specimen collection, microbiology solutions, and molecular diagnostic systems. BD Interventional focuses on surgical, urology, and critical care products. The company also benefits from strategic partnerships with healthcare providers and ongoing innovation in medical technology, which contribute significantly to its earnings.

Becton Dickinson Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes revenue from different business units, highlighting which segments drive growth and profitability, and indicating strategic focus areas for Becton Dickinson.
Chart InsightsBecton Dickinson's Medical segment shows robust growth, with recent quarters outperforming previous levels, indicating strong demand and effective strategic positioning. However, the Life Sciences segment faces headwinds due to reduced global research funding, impacting biosciences sales. Despite these challenges, BD's strategic investments in U.S. manufacturing and product innovation aim to bolster future growth. The earnings call highlights tariff impacts and market pressures in China, which could affect margins and growth projections. Investors should watch for BD's ability to navigate these challenges while leveraging its strong EPS performance and margin improvements.
Data provided by:Main Street Data

Becton Dickinson Earnings Call Summary

Earnings Call Date:May 01, 2025
(Q2-2025)
|
% Change Since: -10.79%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call revealed a mixed performance for BD, with strong adjusted EPS growth and strategic investments being overshadowed by revenue challenges and external market pressures in Life Sciences, Diagnostics, and the China market. Tariff impacts further complicate the outlook.
Q2-2025 Updates
Positive Updates
Adjusted EPS Growth Exceeds Expectations
Despite revenue challenges, BD exceeded their adjusted EPS growth expectations, delivering $3.35 in Q2, representing a 5.7% year-over-year increase.
Strong Margin Performance
BD reported adjusted gross margins of 54.9%, which increased by 190 basis points year-over-year, supported by the BD Excellence program.
Significant U.S. Manufacturing Investment
BD announced plans to invest $2.5 billion in U.S. manufacturing over the next five years to strengthen their position and commitment to a resilient U.S. healthcare system.
Positive Product Launches and Innovations
BD launched several new products like Phasix ST Umbilical and is on track to launch the BD FACSDiscover A8, which have received positive feedback from pilot customers.
Negative Updates
Revenue Growth Below Expectations
Revenues grew 6% or 0.9% organic, below expectations, due to market dynamics in Life Sciences and lower-than-expected recovery in Diagnostics.
Challenges in Life Sciences and Diagnostics
Life Sciences faced reduced global research funding, impacting biosciences instrument sales, while Diagnostics saw softness in the blood culture business.
China Market Decline
BD experienced a double-digit decrease in China sales due to volume-based procurement and ongoing research spending pressure.
Impact of Tariffs
BD expects $90 million in tariff expenses for FY '25, which will impact adjusted EPS by approximately $0.25, predominantly in Q4.
Company Guidance
During BD's Second Fiscal Quarter 2025 Earnings Call, the company provided guidance indicating a revised expectation for organic revenue growth of 3% to 3.5% for the full fiscal year, down from previous projections due to market dynamics impacting the Life Sciences and Diagnostics segments. BD reported Q2 revenue growth of 6%, or 0.9% organically, and an adjusted gross margin of 54.9%, which increased by 190 basis points year-over-year. Despite these challenges, BD exceeded its adjusted EPS growth expectations, delivering an EPS of $3.35, reflecting a 5.7% increase. The company is undertaking strategic actions to reaccelerate organic sales growth, including investments in its Pharm Systems, Alaris, PureWick, and Phasix product lines. Additionally, BD is actively mitigating the impacts of tariffs, estimating a $90 million tariff expense for FY '25, and has committed to a $2.5 billion investment in U.S. manufacturing over the next five years.

Becton Dickinson Financial Statement Overview

Summary
Becton Dickinson maintains strong revenue growth and stable margins. Despite minor concerns like increasing leverage and slightly declining net profit margins, the overall financial health is sound with effective cash flow management.
Income Statement
85
Very Positive
Becton Dickinson shows strong financial performance with a consistent revenue growth trend from $17.12B in 2020 to $20.87B TTM. Gross Profit Margin is healthy, maintaining above 44% consistently, and the Net Profit Margin is stable, though slightly decreased to 7.18% TTM from 8.45% in 2021. EBIT and EBITDA margins demonstrate operational efficiency despite slight declines. Overall, the income statement reflects robust revenue growth and solid profitability, though there is room for improving net margins.
Balance Sheet
78
Positive
The balance sheet displays a strong equity position with $54.47B in stockholders' equity as of TTM, providing a high Equity Ratio of 100% due to total liabilities being restated. The Debt-to-Equity Ratio is moderate, reflecting reasonable leverage but has increased from 0.75 in 2020 to 0.34 TTM. ROE has been consistent but slightly decreased recently, indicating stable returns on equity. The company's solid equity base and manageable leverage suggest financial stability, but increasing net debt warrants monitoring.
Cash Flow
82
Very Positive
Cash flow analysis reveals strong operating cash flows, with $3.30B TTM, and substantial free cash flows, despite a decline from $3.42B in 2021 to $2.59B TTM. The Free Cash Flow to Net Income Ratio remains favorable, highlighting efficient cash conversion. The Operating Cash Flow to Net Income Ratio is robust, ensuring liquidity. Although there are fluctuations, the overall cash flow position is strong, supporting operational and strategic investments.
BreakdownSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue20.18B19.37B18.87B20.25B17.12B
Gross Profit9.13B8.17B8.48B9.43B7.58B
EBITDA4.82B4.28B4.29B4.25B2.97B
Net Income1.71B1.48B1.78B2.09B874.00M
Balance Sheet
Total Assets57.29B52.78B52.93B53.87B54.01B
Cash, Cash Equivalents and Short-Term Investments2.16B1.42B1.01B2.29B2.85B
Total Debt20.11B15.88B16.07B17.61B17.93B
Total Liabilities31.40B26.98B27.63B30.19B30.24B
Stockholders Equity25.89B25.80B25.30B23.68B23.77B
Cash Flow
Free Cash Flow3.07B2.12B1.66B3.42B2.73B
Operating Cash Flow3.80B2.99B2.63B4.65B3.54B
Investing Cash Flow-5.51B-716.00M-3.23B-1.88B-1.23B
Financing Cash Flow2.09B-1.96B-591.00M-3.31B22.00M

Becton Dickinson Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price183.63
Price Trends
50DMA
173.80
Positive
100DMA
190.82
Negative
200DMA
209.94
Negative
Market Momentum
MACD
2.03
Negative
RSI
63.10
Neutral
STOCH
89.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDX, the sentiment is Neutral. The current price of 183.63 is above the 20-day moving average (MA) of 176.85, above the 50-day MA of 173.80, and below the 200-day MA of 209.94, indicating a neutral trend. The MACD of 2.03 indicates Negative momentum. The RSI at 63.10 is Neutral, neither overbought nor oversold. The STOCH value of 89.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BDX.

Becton Dickinson Risk Analysis

Becton Dickinson disclosed 23 risk factors in its most recent earnings report. Becton Dickinson reported the most risks in the "Macro & Political" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Becton Dickinson Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
83
Outperform
$40.08B30.6925.81%0.78%9.54%37.23%
78
Outperform
$16.33B35.7017.72%0.30%2.89%-5.50%
73
Outperform
$14.64B35.595.15%6.88%21.11%
70
Outperform
$52.33B34.845.97%2.22%5.84%15.12%
70
Outperform
$14.70B27.8511.77%1.66%21.95%
56
Neutral
$14.76B136.07-8.96%2.78%-20.17%-138.32%
46
Neutral
C$201.68M-3.28-23.14%1.87%20.75%-0.36%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BDX
Becton Dickinson
183.63
-44.68
-19.57%
BAX
Baxter International
28.77
-5.52
-16.10%
COO
Cooper Co
73.80
-18.88
-20.37%
HOLX
Hologic
66.10
-11.78
-15.13%
RMD
Resmed
273.50
67.02
32.46%
WST
West Pharmaceutical Services
279.10
2.75
1.00%

Becton Dickinson Corporate Events

M&A TransactionsBusiness Operations and Strategy
Becton Dickinson Announces Reverse Morris Trust with Waters
Positive
Jul 14, 2025

On July 13, 2025, Becton, Dickinson and Company announced a Reverse Morris Trust transaction with Waters Corporation, combining its Biosciences and Diagnostic Solutions business with Waters. This strategic move will result in BD receiving approximately $4 billion in cash and its shareholders owning 39.2% of Waters’ common stock. The transaction involves several steps, including the separation of BD’s Biosciences and Diagnostic Solutions Business into a new entity, SpinCo, which will then merge with a subsidiary of Waters. This merger has been approved by both companies’ boards and is expected to enhance BD’s financial position and market influence.

The most recent analyst rating on (BDX) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.

M&A TransactionsBusiness Operations and Strategy
Becton Dickinson Announces $17.5B Merger with Waters
Positive
Jul 14, 2025

On July 14, 2025, Becton Dickinson and Waters Corporation announced a definitive agreement to combine BD’s Biosciences and Diagnostic Solutions business with Waters in a Reverse Morris Trust transaction valued at approximately $17.5 billion. This strategic move aims to create a leading life science and diagnostics company with a strong presence in high-growth markets, doubling Waters’ total addressable market to $40 billion. The combined company is expected to generate significant shareholder value through cost and revenue synergies, with anticipated annualized EBITDA synergies of $345 million by 2030. The transaction is expected to be accretive to adjusted EPS in the first year, with a promising financial outlook projecting mid-to-high single-digit revenue growth and mid-teens adjusted EPS growth over the next five years.

The most recent analyst rating on (BDX) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.

Legal Proceedings
Becton Dickinson Reaches Proposed Settlement in Derivative Case
Neutral
Jun 16, 2025

Becton, Dickinson and Company (BD) is involved in a legal matter concerning stockholder derivative actions. A proposed settlement has been reached in the consolidated stockholder derivative litigation against BD and certain of its officers and directors, which alleges breaches of fiduciary duties and other misconduct related to the Alaris infusion pump system. The settlement, if approved by the court, will resolve the litigation and prevent further claims related to the issues. A settlement hearing is scheduled for August 11, 2025, to determine the fairness of the settlement terms.

The most recent analyst rating on (BDX) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 23, 2025